An Open-Label Pilot Study of Losmapimod to Evaluate the Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments in Subjects With Facioscapulohumeral Muscular Dystrophy 1 (FSHD1) with Extension

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512736-29-00

Acronym

FIS-001-2019

Enrollment

Registered

2024-06-11

Start date

2019-08-23

Completion date

2024-10-31

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Facioscapulohumeral Muscular Dystrophy 1 (FSHD1)

Brief summary

Safety and tolerability based on AEs, clinical laboratory test results, ECGs, and vital signs.

Interventions

DRUGLosmapimod

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Safety and tolerability based on AEs, clinical laboratory test results, ECGs, and vital signs.	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026